Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of high dose toremifene for metastatic breast cancer after failure of adjuvant therapy of aromatase inhibitor.

Next Previous
X
Search
Trial Profile

Study of high dose toremifene for metastatic breast cancer after failure of adjuvant therapy of aromatase inhibitor.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toremifene (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Sep 2011 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 06 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 05 Oct 2006 The expected completion date for this trial is now 1 Aug 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top